Cyhoeddiad
2023
- Beresford, M. et al. 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1(1), article number: 13. (10.1038/s44276-023-00016-8)
2021
- Jayson, G. et al. 2021. VALTIVE1: Validation of Tie2 as a response biomarker for VEGF inhibitors In Ovarian Cancer. Presented at: NCRI Cancer Conference, 2021.
2020
- Jones, R. H. et al. 2020. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 21(3), pp. 345-347. (10.1016/S1470-2045(19)30817-4)
2018
- Hurt, C. N. et al. 2018. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multi-centre, randomised, phase II trial (RT3VIN). BJOG: An International Journal of Obstetrics and Gynaecology 125(9), pp. 1171-1177. (10.1111/1471-0528.15124)
Cynadleddau
- Jayson, G. et al. 2021. VALTIVE1: Validation of Tie2 as a response biomarker for VEGF inhibitors In Ovarian Cancer. Presented at: NCRI Cancer Conference, 2021.
Erthyglau
- Beresford, M. et al. 2023. Fulvestrant plus vandetanib versus placebo for the treatment of patients with metastatic breast cancer resistant to aromatase inhibitor therapy (FURVA): a multicentre, Phase 2, randomised controlled trial. BJC Reports 1(1), article number: 13. (10.1038/s44276-023-00016-8)
- Jones, R. H. et al. 2020. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet Oncology 21(3), pp. 345-347. (10.1016/S1470-2045(19)30817-4)
- Hurt, C. N. et al. 2018. Recurrence of vulval intraepithelial neoplasia following treatment with cidofovir or imiquimod: results from a multi-centre, randomised, phase II trial (RT3VIN). BJOG: An International Journal of Obstetrics and Gynaecology 125(9), pp. 1171-1177. (10.1111/1471-0528.15124)